Indication
Hyperlipidemia
Hyperlipidemia is a metabolic disorder characterized by abnormally elevated systemic concentrations of lipids or lipoproteins, including low-density lipoprotein cholesterol (LDL-C), total cholesterol, and triglycerides. Read more about Hyperlipidemia
384 drugs 151 manufacturers
Drugs that treat it
Common Hyperlipidemia therapies.
EZETIMIBE
FENOFIBRATE
FENOFIBRATE (fenofibrate nanocrystallized)
FENOFIBRATE (fenofibrate nanocrystallized)
FENOFIBRIC ACID (fenofibric acid (choline))
FIBRICOR (fenofibric acid)
FENOFIBRATE (fenofibrate,micronized)
EZETIMIBE
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonHyperlipidemia is a metabolic disorder characterized by abnormally elevated systemic concentrations of lipids or lipoproteins, including low-density lipoprotein cholesterol (LDL-C), total cholesterol, and triglycerides.
Primarily impacting the cardiovascular and vascular systems across pediatric and adult populations, the condition stems from primary genetic mutations or secondary factors such as obesity, diabetes, and dietary intake.
Pathophysiologically, altered lipid synthesis, transport, or clearance leads to the accumulation of atherogenic circulating particles that deposit within the vascular endothelium.
This process accelerates systemic atherogenesis, substantially elevating the long-term clinical risk for coronary artery disease, myocardial infarction, and ischemic stroke.
- nih.gov
Hyperlipidemia is a metabolic disorder characterized by abnormally elevated systemic concentrations of lipids or lipoproteins, including low-density lipoprotein cholesterol (LDL-C), total cholesterol, and triglycerides
- nih.gov
Hyperlipidemia is a metabolic disorder characterized by abnormally elevated systemic concentrations of lipids or lipoproteins, including low-density lipoprotein cholesterol (LDL-C), total cholesterol, and triglycerides
- nih.gov
Primarily impacting the cardiovascular and vascular systems across pediatric and adult populations, the condition stems from primary genetic mutations or secondary factors such as obesity, diabetes, and dietary intake
- cdc.gov
Primarily impacting the cardiovascular and vascular systems across pediatric and adult populations, the condition stems from primary genetic mutations or secondary factors such as obesity, diabetes, and dietary intake
- nih.gov
Pathophysiologically, altered lipid synthesis, transport, or clearance leads to the accumulation of atherogenic circulating particles that deposit within the vascular endothelium
- clevelandclinic.org
Pathophysiologically, altered lipid synthesis, transport, or clearance leads to the accumulation of atherogenic circulating particles that deposit within the vascular endothelium
- nih.gov
Pathophysiologically, altered lipid synthesis, transport, or clearance leads to the accumulation of atherogenic circulating particles that deposit within the vascular endothelium
- cdc.gov
This process accelerates systemic atherogenesis, substantially elevating the long-term clinical risk for coronary artery disease, myocardial infarction, and ischemic stroke
- nih.gov
This process accelerates systemic atherogenesis, substantially elevating the long-term clinical risk for coronary artery disease, myocardial infarction, and ischemic stroke
- nih.gov
This process accelerates systemic atherogenesis, substantially elevating the long-term clinical risk for coronary artery disease, myocardial infarction, and ischemic stroke
Personalize your experience
Follow Hyperlipidemia and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.